
Valneva SE (VALN) Stock Forecast & Price Target
Valneva SE (VALN) Analyst Ratings
Bulls say
Valneva SE has demonstrated a positive outlook due to the increased confidence in the commercial uptake of its Lyme vaccine candidate, VLA15, particularly as assumptions for Europe align more closely with those in the US. The company reported strong immune responses following a third yearly booster for the VLA15 vaccine, suggesting promising efficacy that may enhance future market potential. Despite a recent suspension of the Ixchiq vaccine by the FDA, overall earnings have met expectations, indicating stability as Valneva continues to focus on its robust pipeline and commitment to developing life-saving vaccines.
Bears say
Valneva SE faces significant risks including potential clinical and regulatory setbacks, which could adversely impact product sales and market competitiveness. Specific safety concerns related to its vaccine IXCHIQ have diminished its competitive edge against alternatives, such as Bavarian Nordic's chikungunya vaccine, despite claims of superior long-term protection. Furthermore, the removal of projected U.S. sales for IXCHIQ and expectations for limited uptake in Europe due to these concerns and emerging competition contribute to a negative outlook on the company's stock performance.
This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.
Valneva SE (VALN) Analyst Forecast & Price Prediction
Start investing in Valneva SE (VALN)
Order type
Buy in
Order amount
Est. shares
0 shares